Michele Golino

Dr. Michele Golino

Virginia Commonwealth University, Richmond, California, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Nadia Martinez NayaNadia Martinez Naya
Nadia Martinez Naya
JKJazmin Kelly
Jazmin Kelly
GCGiuliana Corna
Giuliana Corna
Michele GolinoMichele Golino
Michele Golino
AAAntonio Abbate
Antonio Abbate
STStefano Toldo
Stefano Toldo
Cannabidiol (CBD) is the primary non-psychoactive chemical from Cannabis Sativa, a plant used for centuries for both recreational and medicinal purposes. CBD lacks the psychotropic effects of Δ9-tetrahydrocannabinol (Δ9-THC) and has shown great therapeutic potential. CBD exerts a wide spectrum of effects at a molecular, cellular, and organ level, affecting inflammation, oxidative damage, cell survival, pain, vasodilation, and excitability, among others, modifying many physiological and pathophysiological processes. There is evidence that CBD may be effective in treating several human disorders, like anxiety, chronic pain, psychiatric pathologies, cardiovascular diseases, and even cancer. Multiple cellular and pre-clinical studies using animal models of disease and several human trials have shown that CBD has an overall safe profile. In this review article, we summarize the pharmacokinetics data, the putative mechanisms of action of CBD, and the physiological effects reported in pre-clinical studies to give a comprehensive list of the findings and major effects attributed to this compound.

18 January 2024 in Molecules
Verified
Journal Article
Open access
PDF file
Nadia Martinez NayaNadia Martinez Naya
Nadia Martinez Naya
JKJazmin Kelly
Jazmin Kelly
GCGiuliana Corna
Giuliana Corna
Michele GolinoMichele Golino
Michele Golino
APAriel H. Polizio
Ariel H. Polizio
EMEleonora Mezzaroma
Eleonora Mezzaroma
Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis Sativa, has garnered increasing attention for its diverse therapeutic potential. This comprehensive review delves into the complex pharmacokinetics of CBD, including factors such as bioavailability, distribution, safety profile, and dosage recommendations, which contribute to the compound’s pharmacological profile. CBD’s role as a pharmacological inhibitor is explored, encompassing interactions with the endocannabinoid system and ion channels. The compound’s anti-inflammatory effects, influencing the Interferon-beta and NF-κB, position it as a versatile candidate for immune system regulation and interventions in inflammatory processes. The historical context of Cannabis Sativa’s use for recreational and medicinal purposes adds depth to the discussion, emphasizing CBD’s emergence as a pivotal phytocannabinoid. As research continues, CBD’s integration into clinical practice holds promise for revolutionizing treatment approaches and enhancing patient outcomes. The evolution in CBD research encourages ongoing exploration, offering the prospect of unlocking new therapeutic utility.

28 April 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
ACArturo Cesaro
Arturo Cesaro
Daniele PastoriDaniele Pastori
Daniele Pastori
VAVincenzo Acerbo Acerbo
Vincenzo Acerbo Acerbo
FBFlavio Giuseppe Biccirè
Flavio Giuseppe Biccirè
Michele GolinoMichele Golino
Michele Golino
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Aims: This meta-analysis aims to evaluate the effect of semaglutide, a glucagon-like peptide-1 receptor agonist, on new-onset atrial fibrillation (AF) in randomized clinical trials (RCTs). Methods and results: Twenty-six RCTs involving 48 583 participants (of whom 25 879 on semaglutide) with 541 new-onset AF were analyzed. Semaglutide treatment resulted in a 17% reduction in AF incidence compared to controls (odds ratio [OR] 0.83, 95% confidence interval [CI] 0.70–0.98, P = 0.03) with no heterogeneity (I² = 0%). The effect was more pronounced with the oral formulation, which reduced AF incidence by 52% (OR 0.48, 95% CI 0.24–0.95, P = 0.04), while studies with active comparators showed a 59% reduction in AF risk (OR 0.41, 95% CI 0.20–0.83, P = 0.01). In trials without sodium-glucose co-transporter 2 inhibitors (SGLT2i) concomitant therapy, there was a significant reduction of 21% in new-onset AF (OR 0.79, 95% CI, 0.63–0.99; P = 0.04). Meta-regression revealed no influence of baseline covariates, including BMI and HbA1c. An additional meta-regression analysis evaluating the percentage of patients on SGLT2 inhibitors as a potential moderator revealed no statistically significant association (P = 0.336). Conclusion: Treatment with semaglutide significantly reduces the incidence of new-onset AF. This effect appears more evident with the oral formulation and independent of baseline characteristics.

24 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MPMaria Alexandra Pană
Maria Alexandra Pană
ABAristi Boulmpou
Aristi Boulmpou
CICigdem Ileri
Cigdem Ileri
GMGiovanna Manzi
Giovanna Manzi
Michele GolinoMichele Golino
Michele Golino
FPFrancesco Perone
Francesco Perone
Coronary artery disease is the leading cause of acute and chronic heart failure. Patients with heart failure and ischemic heart disease need a tailored assessment to define the appropriate treatment, while a specific multidisciplinary management plan should be followed. Indeed, several factors should be assessed before starting treatment, such as heart failure symptoms and/or signs, angina, electrocardiographic features, right and left ventricular systolic and diastolic function, serological abnormalities, cardiac structural and functional integrity, and pulmonary function. New scenarios and developments have emerged recently in this field, increasing our knowledge regarding pathophysiology, exercise, and pharmacology. Effective and appropriate management and treatment reduce the risk of death and hospitalization for heart failure. Herein, we provide an updated, state-of-the-art overview of pharmacological treatment and cardiac rehabilitation in patients with chronic heart failure and coronary artery disease. Furthermore, tailored and contemporary management in clinical practice will be proposed for this specific and fragile patient population.

3 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
GLGaetano Antonio Lanza
Gaetano Antonio Lanza
Michele GolinoMichele Golino
Michele Golino
AVAngelo Villano
Angelo Villano
OLOreste Lanza
Oreste Lanza
PLPriscilla Lamendola
Priscilla Lamendola
MLMassimo Leggio
Massimo Leggio
Endothelial dysfunction is an early abnormality in the process of atherosclerosis and cardiovascular disease and has been associated with worse clinical outcome. Cardiac rehabilitation (CR) has been reported to be helpful to reduce cardiovascular events in various types of cardiac disease, but the mechanisms of its beneficial effects remain only partially known. In this article, we review the studies that assessed the effect of CR on endothelial function in patients with various cardiac conditions. Available data show that CR significantly improves impaired endothelial function in these patients, which may contribute to the beneficial effects of CR on clinical outcome.

Verified
Journal Article
Open access
PDF file
JMJacopo Marazzato
Jacopo Marazzato
FBFederico B. M. Blasi
Federico B. M. Blasi
Michele GolinoMichele Golino
Michele Golino
Paolo VerdecchiaPaolo Verdecchia
Paolo Verdecchia
Fabio AngeliFabio Angeli
Fabio Angeli
Roberto De PontiRoberto De Ponti
Roberto De Ponti
Because of demographic aging, the prevalence of arterial hypertension (HTN) and cardiac arrhythmias, namely atrial fibrillation (AF), is progressively increasing. Not only are these clinical entities strongly connected, but, acting with a synergistic effect, their association may cause a worse clinical outcome in patients already at risk of ischemic and/or haemorrhagic stroke and, consequently, disability and death. Despite the well-known association between HTN and AF, several pathogenetic mechanisms underlying the higher risk of AF in hypertensive patients are still incompletely known. Although several trials reported the overall clinical benefit of renin–angiotensin–aldosterone inhibitors in reducing incident AF in HTN, the role of this class of drugs is greatly reduced when AF diagnosis is already established, thus hinting at the urgent need for primary prevention measures to reduce AF occurrence in these patients. Through a thorough review of the available literature in the field, we investigated the basic mechanisms through which HTN is believed to promote AF, summarising the evidence supporting a pathophysiology-driven approach to prevent this arrhythmia in hypertensive patients, including those suffering from primary aldosteronism, a non-negligible and under-recognised cause of secondary HTN. Finally, in the hazy scenario of AF screening in hypertensive patients, we reviewed which patients should be screened, by which modality, and who should be offered oral anticoagulation for stroke prevention.